Wedbush Maintains Outperform on Viridian Therapeutics, Raises Price Target to $42
Benzinga Newsdesk 3 hours ago
Analyst RatingsNewsPrice Target
Wedbush analyst Laura Chico maintains Viridian Therapeutics (NASDAQ:VRDN) with a Outperform and raises the price target from $41 to $42.
Wedbush analyst Laura Chico maintains Viridian Therapeutics (NASDAQ:VRDN) with a Outperform and raises the price target from $41 to $42.